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production, suggesting that Th17 cells may be more resistant to suppression than Th1 cells (11, 12) . However, the apparent ineffectiveness of human nTreg cells in regulating Th17 cells is at variance with data from mouse models, which have demonstrated that CD4 + CD25 + Treg cells can control autoimmune inflammation (13, 14) .
nTreg cells in mice and humans express the transcription factor Foxp3, which is required for directing their function (15, 16) . Foxp3 and CD25 hi expression have also been negatively correlated with CD127, and exclusion of CD127 hi cells eliminates recently activated cells (17, 18) . Recently, CD39 was found to be expressed on a subpopulation of Treg cells (19, 20) . CD39
is an ectonucleotidase which cleaves ATP in a rate limiting step to form AMP, which can then be cleaved by CD73 to form adenosine (19, 20 The adenosine agonist 2-chloro-adenisine (Tocris) was used at 1 or 10 µM. The adenosine antagonist ZM241385 or the CD39 ectonucleotidase inhibitor POM-1 (both Tocris), were added to suppression assays at a concentration of 1 µM. Neutralising antibodies specific for IL-10 (R&D Systems) and TGF-β (a kind gift from Louis Boon, Bioceros BV, Utrecht, The Netherlands) were added to suppression assays at 10 µg/ml.
Materials and Methods

Patients and blood samples
Analysis of Treg cell subsets by flow cytometry
PBMC from MS patients and healthy controls were stained ex vivo with CD4-PerCP (BD Biosciences), CD39-FITC, CD25-PECy7, CD127-Alexa647 followed by fixation, permeabilisation and intracellular staining with Foxp3-PE (all eBioscience). Cells were acquired on a Beckman Coulter CyAn flow cytometer and analysed using FlowJo software. Analysis of cell surface TGF-β and LAP was performed on sorted Treg cell subsets stimulated for 5 days with anti-CD3 plus irradiated APC. Cells were stained using TGF-β-PE (IQ Products) and biotinylated latency associated protein (LAP) (R&D Systems) followed by detection with streptavidin-PerCP (Becton Dickinson).
Results
CD39 + Treg cells suppress IL-17 production by effector T cells.
It has previously been reported that human CD4 + CD25 + nTreg cells do not suppress IL-17
production by Th17 cells (11, 12 and in fact enhanced IL-17 production over a range of Treg to responder T cell ratios (Fig. 3A) . We found that CD39 + Treg cells from MS patients suppressed IFN-γ to a similar extent as those from normal controls individuals (Fig. 6A) . However, when compared with normal individuals, CD39 + Treg cells from MS patients exhibited a significantly impaired capacity to suppress IL-17 production (Fig. 6A) . In order to determine whether this was due to increased resistance to suppression by CD25 -responder T cells from MS patients, or due to a defect in the Treg cells, we performed cross-over experiments using responder T cells from control cells co-cultured with
Treg cells from MS patients and vice versa. We found that CD39 + Treg cells from normal controls effectively suppressed IL-17 production by responder T cells from control or MS patients (Fig. 6B) . However, we demonstrated that CD39 + Treg cells from MS patients were less effective at suppressing IL-17 production by responder T cells from MS patients (Fig. 6B ). These findings indicate that the defect in regulation of IL-17 production in MS reflect a defect in numbers and function of CD39 + Treg cells in these patients. and IFN-γ. Increasing doses of 2-chloro-adenosine, a stable adenosine analogue, efficiently suppressed proliferation, as well as IFN-γ and IL-17 production by responder T cells (Fig. 7A ).
The mechanism of suppression of IL-17 production by CD39 + Treg cells
The findings suggest that CD39 + Treg cells could potentially suppress via hydrolysis of ATP and production of adenosine.
We next investigated the effects of blocking ATP hydrolysis by CD39. CD4 + responder T cells were stimulated with anti-CD3 and APC in the presence of POM-1, an inhibitor of CD39 ectonucleotidase activity, or ZM241385, which inhibits the binding of adenosine to its A2A receptor, and cytokine production was measured after 3 days. Addition of POM-1 or ZM241385, did not reverse the suppressive effect of CD39 + Treg cells (Fig. 7B) . However, blockade of CD39 activity significantly enhanced IL-17 production and had little effect on IFN-γ by responder T cells (Fig. 7B ). This suggested that extracellular ATP promotes IL-17, and that CD39 ectonucleotidase activity could reduce IL-17 via removal of ATP.
Since we had shown that after stimulation CD4 + CD25 hi CD39 -T cells secreted IL-10 and CD4 + CD25 hi CD39 + cells expressed high levels of TGF-β, we next investigated a possible role for these cytokines in mediating suppression. However, addition of a neutralising antibody specific for TGF-β failed to abrogate suppression by CD39 + Treg cells (Fig 7C) . Furthermore, we could find no evidence of a role for IL-10 in mediating suppression by the CD39 + or CD39 -subsets, since a blocking IL-10 antibody did not reverse suppression (Fig 7D) .
We next examined the requirement for cell contact versus soluble factors. Using a transwell culture system, we found that suppression of IFN-γ by CD39 -Treg cells and IFN-γ and IL-17 by the CD39 + Treg cell subset required contact between the regulatory and responder T cells, as suppression was abrogated when they were separated by a semi-permeable membrane (Fig. 7E) . This is consistent with our findings that anti-IL-10 or anti-TGF-β failed to reverse suppression by CD39 + or CD39 -Treg cells. These findings suggest that suppression by CD4 + CD25 hi CD39 + cells is not mediated by IL-10 and TGF-β in vitro, but does require cell contact and while it could not be reversed by inhibitors of an inhibitor of CD39 ectonucleotidase activity, could be duplicated by adenosine.
Discussion
There is now convincing evidence from animal models that the failure to regulate inflammatory T cells that secrete IL-17 is central to the development of autoimmune diseases (23) . However, all the evidence to date suggests that human Foxp3 + Treg cells, while capable of suppressing proliferation and IFN-γ production, do not suppress IL-17 production by effector T cells (11, 12, 24) . In this study we demonstrate for the first time that a subset of human + displayed no significant defect in ability to suppress IFN-γ production. However the study by Michel and colleagues (7) did not examine the ability of Treg cells from MS patients to suppress IL-17 production. We found that CD4 + CD25 + CD127 lo CD39 + cells from MS patients were less effective in suppressing IL-17 production than those from normal individuals.
There has been some suggestion that Th17 cells may be more difficult to suppress than Cytokines and proliferation were analysed on day 3. *** p<0.001 Student's t-test. 
